Add like
Add dislike
Add to saved papers

Suppression of IKK, but not activation of p53 is responsible for cell death mediated by naturally occurring oxidized tetranortriterpenoid.

Tetranortriterpenoids (limonoids) obtained from the neem tree (Azadirachta indica) have gained significant attention due to their anti-proliferative properties. Here we are investigating the role of a highly oxidized tetranortriterpenoid, azadirachtin on induction of the cell death. Using various apoptotic assays, we show that azadirachtin induces cell death independent of cell types. Although azadirachtin-treated cells show increased expression of p53, but no phosphorylation of p53 (at Ser15 and Ser46) is detected. In silico analysis reveals that azadirachtin interacts with Mdm2 in the p53 binding site, postulating the mutually exclusive interaction of p53 and azadirachtin with Mdm2. Surprisingly, azadirachtin potentiates cell death efficiently in both p53 wild-type and p53 negative cells. In addition, we find azadirachtin suppresses nuclear transcription factor kappaB (NF-κB) by inhibiting the phosphorylation of upstream inhibitory subunit of NF-κB (IκB) kinase (IKK). Further, azadirachtin is unable to potentiate apoptosis in NF-κB-downregulated (IκB-DN) cells, whereas ectopic expression of p65 rescues azadirachtin-mediated apoptosis, regardless of their p53 status. Hence, our data suggest that azadirachtin mediates cell death through inhibition of NF-κB, but not due to the activation of p53. In conclusion, this study proposes azadirachtin as a potential therapeutic agent where insensitivity toward chemotherapy occurs due to the inactivation or mutations in p53.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app